Betulinic acid restores imatinib sensitivity in BCR‐ABL1 kinase−independent, imatinib‐resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation-Reference-Cited by-同舟云学术

Betulinic acid restores imatinib sensitivity in BCR‐ABL1 kinase−independent, imatinib‐resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation

Published:2020-01-13 Issue:1 Volume:1467 Page:77-93
ISSN:0077-8923
Container-title:Annals of the New York Academy of Sciences
language:en
Short-container-title:Ann. N.Y. Acad. Sci.

Author:

Lu Tingting¹²³^ORCID,Wei Danna¹⁴⁵,Yu Kunlin¹⁴⁵⁶,Ma Dan¹⁴⁵,Xiong Jie¹⁴⁵,Fang Qin⁶,Wang Jishi¹⁴⁵

Affiliation:

1. Department of HaematologyAffiliated Hospital of Guizhou Medical University Guizhou China

2. Department of Clinical Laboratory CentreAffiliated Hospital of Guizhou Medical University Guizhou China

3. School of Basic Medical SciencesGuizhou Medical University Guizhou China

4. Hematological Institute of Guizhou Province Guizhou China

5. Guizhou Province Hematopoietic Stem Cell Transplantation Centre and Key Laboratory of Hematological Disease Diagnostic and Treatment Centre Guizhou China

6. Department of PharmacyAffiliated Hospital of Guizhou Medical University Guizhou China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

History and Philosophy of Science,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/nyas.14298

Reference61 articles.

1. Chronic myeloid leukaemia as a model of disease evolution in human cancer

2. Constitutive activation of STAT5 by the BCR‐ABL oncogene in chronic myelogenous leukemia;Shuai K.;Oncogene,1996